Hospital
Pasco-Pinellas Hillsborough Community Health System INC
Pasco-Pinellas Hillsborough Community Health System INC was paid $7.64M by Medicaid between Jan 2018 and Nov 2024, across 167 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoPASCO-PINELLAS HILLSBOROUGH COMMUNITY HEALTH SYSTEM INC
WESLEY CHAPEL, FL 33544
WESLEY CHAPEL, FL 33544
33aNPI1073893020assigned 08/23/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.64M
24GClaims353,161
24DCodes billed167
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#65 of 163
Median peer was paid$4.77M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,773 | $259K | |
| 2019 | 80,084 | $1.47M | |
| 2020 | 66,293 | $1.34M | |
| 2021 | 78,915 | $1.68M | |
| 2022 | 63,492 | $1.42M | |
| 2023 | 28,748 | $1.07M | |
| 2024incomplete | 7,856 | $400K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 18,842 | 16,659 | $1.24M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 17,809 | 14,778 | $1.10M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 7.7% | 5,279 | 4,282 | $586K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.2% | 10,659 | 8,485 | $552K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.3% | 8,957 | 7,315 | $483K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 5.1% | 2,344 | 1,950 | $390K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 3,346 | 2,772 | $357K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 3,640 | 2,891 | $298K |
| 80053 | Comprehensive metabolic panel | 2.4% | 23,916 | 18,051 | $184K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 2,617 | 2,334 | $165K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 7,410 | 5,425 | $162K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 3,581 | 1,092 | $155K |
155 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 6,352 | $153K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 2,762 | $141K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.2% | 3,004 | $95K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 735 | $82K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 773 | $81K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 1,856 | $81K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 2,227 | $81K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,885 | $66K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,189 | $64K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 380 | $60K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,222 | $55K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 299 | $53K |
| 81001 | <1% | 9,581 | $46K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,377 | $43K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,169 | $43K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 664 | $43K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,304 | $40K |
| G0378 | Hospital observation service, per hour | <1% | 4,810 | $39K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 944 | $36K |
| 82947 | <1% | 4,617 | $33K | |
| 87430 | <1% | 2,892 | $31K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,874 | $28K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 979 | $27K |
| 86850 | <1% | 938 | $26K | |
| 81025 | <1% | 2,115 | $24K | |
| 73610 | <1% | 421 | $24K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,497 | $22K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 917 | $21K |
| 81003 | <1% | 4,287 | $20K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 27,747 | $20K |
| 76830 | Ultrasound, transvaginal | <1% | 519 | $19K |
| 86901 | <1% | 1,739 | $19K | |
| 92587 | <1% | 503 | $19K | |
| 01999 | <1% | 1,381 | $18K | |
| 73630 | <1% | 545 | $16K | |
| 93976 | <1% | 199 | $16K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,511 | $15K |
| 84484 | <1% | 11,328 | $13K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 499 | $13K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 927 | $12K |
| 73130 | <1% | 198 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,661 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,290 | $8K |
| 96376 | <1% | 2,856 | $8K | |
| 80050 | General health panel | <1% | 457 | $8K |
| 83735 | <1% | 4,457 | $7K | |
| 87186 | <1% | 1,144 | $7K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 474 | $7K |
| 73110 | <1% | 107 | $7K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 425 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 380 | $6K |
| 97162 | <1% | 86 | $6K | |
| 93971 | <1% | 283 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,473 | $6K |
| 84702 | <1% | 1,904 | $6K | |
| 82077 | <1% | 569 | $6K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 673 | $6K |
| 92650 | <1% | 130 | $5K | |
| 85730 | <1% | 2,346 | $5K | |
| 73030 | <1% | 177 | $5K | |
| 87210 | <1% | 644 | $5K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 27 | $5K |
| 84703 | <1% | 7,613 | $4K | |
| 76801 | <1% | 876 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 768 | $4K |
| 85610 | <1% | 2,772 | $4K | |
| 87040 | <1% | 5,316 | $4K | |
| 87070 | <1% | 1,909 | $4K | |
| 83605 | <1% | 3,761 | $4K | |
| 83690 | <1% | 6,106 | $4K | |
| 86900 | <1% | 1,724 | $3K | |
| 59025 | Fetal non-stress test | <1% | 49 | $3K |
| 83880 | <1% | 2,576 | $3K | |
| 97161 | <1% | 63 | $3K | |
| 74022 | <1% | 223 | $2K | |
| 87807 | <1% | 847 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,104 | $2K |
| 73564 | <1% | 56 | $2K | |
| 80061 | Lipid panel | <1% | 1,739 | $2K |
| 12001 | <1% | 29 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 892 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,063 | $2K |
| 85027 | <1% | 822 | $2K | |
| 97163 | <1% | 118 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 217 | $2K |
| 85379 | <1% | 1,783 | $2K | |
| 74019 | <1% | 31 | $2K | |
| 97116 | <1% | 236 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,369 | $1K |
| 73562 | <1% | 30 | $1K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 41 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,145 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 838 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 969 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,596 | $1K |
| 12011 | <1% | 13 | $1K | |
| 74018 | <1% | 65 | $1K | |
| 82550 | <1% | 839 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,090 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,008 | $1K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 17 | $905.54 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 215 | $860.51 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 13 | $761.43 |
| 73080 | <1% | 17 | $737.02 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,088 | $588.96 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 497 | $502.89 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,132 | $489.59 |
| J2704 | Injection, propofol, 10 mg | <1% | 181 | $454.53 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $398.13 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,048 | $319.77 |
| 84145 | <1% | 402 | $308.12 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 857 | $245.00 |
| 86140 | <1% | 745 | $215.08 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,209 | $179.49 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 18 | $172.09 |
| 80076 | <1% | 56 | $170.93 | |
| 85652 | <1% | 199 | $153.20 | |
| 90715 | <1% | 69 | $133.17 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 397 | $124.35 |
| 93880 | <1% | 16 | $103.63 | |
| 86308 | <1% | 13 | $91.78 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 76 | $89.96 |
| 82565 | <1% | 18 | $88.75 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,007 | $85.83 |
| 87077 | <1% | 894 | $55.88 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,465 | $42.19 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 49 | $38.04 |
| 72131 | <1% | 18 | $32.65 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 39 | $28.30 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 39 | $25.62 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 60 | $25.24 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 16 | $15.58 |
| 84100 | <1% | 523 | $4.63 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 15 | $0.22 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 69 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 67 | $0.00 |
| 84132 | 0% | 56 | $0.00 | |
| 87486 | 0% | 17 | $0.00 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 26 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 20 | $0.00 |
| 87081 | 0% | 167 | $0.00 | |
| 87581 | 0% | 16 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 39 | $0.00 |
| 82607 | 0% | 57 | $0.00 | |
| 82728 | 0% | 13 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 69 | $0.00 |
| 84439 | 0% | 20 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 36 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 68 | $0.00 |
| 80179 | 0% | 65 | $0.00 | |
| 85007 | 0% | 13 | $0.00 | |
| 87420 | 0% | 22 | $0.00 | |
| 80143 | 0% | 27 | $0.00 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 37 | $0.00 |
| 83540 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFISHER, JOHNATHAN (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Pasco-Pinellas Hillsborough Community Health System INC | Wesley Chapel, FL | $466K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.